Headcount soars at Cambridge gene editing biotechs as trials near – Boston Business Journal
Boston Business Journal |
Headcount soars at Cambridge gene editing biotechs as trials near
Boston Business Journal CRISPR/Cas9 has yet to be tested in humans in the U.S., but excitement surrounding the gene editing technology has already prompted significant employment gains at three publicly traded startups based in Cambridge. Intellia Therapeutics (Nasdaq: NTLA … Zacks Investment Research Upgrades Crispr Therapeutics (CRSP) to “Hold” |
